Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Elderly DLBCL updates

Graham Collins • 7 Dec 2019
ASH 2019
Anemias B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Cyclophosphamide Doxorubicin Lenalidomide Prednisone Vincristine

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares his highlights from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Dr Collins specifically discusses news relating to elderly patients with diffuse large B-cell lymphoma (DLBCL).

More from Graham Collins

Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain 3:22
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
Graham Collins • 28 May 2025
How the Hodgkin lymphoma treatment landscape has evolved: BV-AVD, nivolumab-AVD, BrECADD & more 4:46
How the Hodgkin lymphoma treatment landscape has evolved: BV-AVD, nivolumab-AVD, BrECADD & more
Graham Collins • 28 May 2025
Long-term surveillance for cardiac toxicities in patients with HL treated with chemotherapy 1:34
Long-term surveillance for cardiac toxicities in patients with HL treated with chemotherapy
Graham Collins • 16 Jun 2024
Updates from the Phase II ANIMATE trial of nivolumab in R/R cHL 1:44
Updates from the Phase II ANIMATE trial of nivolumab in R/R cHL
Graham Collins • 16 Jun 2024

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals